{
    "clinical_study": {
        "@rank": "5036", 
        "arm_group": {
            "arm_group_label": "Neoadjuvant docetaxel and carboplatin", 
            "arm_group_type": "Experimental"
        }, 
        "brief_summary": {
            "textblock": "This is a single arm open label phase II study in women with clinical stage 2 or 3 triple\n      negative breast cancer to assess the anti-tumor activity (in terms of pathologic complete\n      response rate) of neoadjuvant docetaxel in combination with carboplatin. Patient derived\n      xenografts will also be developed simultaneously for the purposes of genoproteomic analysis."
        }, 
        "brief_title": "Neoadjuvant Treatment of Triple Negative Breast Cancer Patients With Docetaxel and Carboplatin to Assess Anti-tumor Activity", 
        "completion_date": {
            "#text": "April 2022", 
            "@type": "Anticipated"
        }, 
        "condition": "Triple Negative Breast Neoplasms", 
        "condition_browse": {
            "mesh_term": [
                "Breast Neoplasms", 
                "Neoplasms"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Newly diagnosed clinical stage II or III breast cancer with complete surgical\n             excision of the breast cancer after neoadjuvant chemotherapy as the treatment goal.\n\n          -  Patients with PR+ tumors are allowed.\n\n          -  HER2 negative by FISH or IHC staining 0 or 1+.\n\n          -  ER less than Allred score of 3 or less than 1% positive staining cells in the\n             invasive component of the tumor\n\n          -  Tumor size at least 2cm in one dimension by clinical or radiographic exam (WHO\n             criteria).\n\n          -  At least 18 years of age.\n\n          -  ECOG performance status \u2264 2\n\n          -  Normal bone marrow and organ function as defined below:\n\n               -  Leukocytes \u2265 3,000/mcL\n\n               -  Absolute neutrophil count \u2265 1,500/mcl\n\n               -  Platelets \u2265 100,000/mcl\n\n               -  Serum bilirubin within (or under ) normal limits (OR total bilirubin \u2264 3.0 x\n                  IULN with direct bilirubin within normal range in patients with well documented\n                  Gilbert Syndrome)\n\n               -  AST(SGOT)/ALT(SGPT) within (or under ) normal limits\n\n               -  Creatinine within (or under) normal institutional limits OR creatinine clearance\n                  \u2265  60 mL/min/1.73 m2 for patients with creatinine levels above institutional\n                  normal\n\n          -  Patients may be pre- or post-menopausal. Women of childbearing potential must agree\n             to use adequate contraception (hormonal or barrier method of birth control,\n             abstinence) prior to study entry and for the duration of study participation.  Should\n             a woman become pregnant or suspect she is pregnant while participating in this study,\n             she must inform her treating physician immediately.\n\n          -  Ability to understand and willingness to sign an IRB approved written informed\n             consent document (or that of legally authorized representative, if applicable).\n\n        Exclusion Criteria:\n\n          -  Prior systemic therapy for the indexed breast cancer.\n\n          -  A history of other malignancy \u2264 5 years previous with the exception of basal cell or\n             squamous cell carcinoma of the skin which were treated with local resection only or\n             carcinoma in situ of the cervix.\n\n          -  Patients with bilateral or inflammatory breast cancer.\n\n          -  Currently receiving any other investigational agents.\n\n          -  A history of allergic reactions attributed to compounds of similar chemical or\n             biologic composition to docetaxel or carboplatin.\n\n          -  Uncontrolled intercurrent illness including, but not limited to, ongoing or active\n             infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac\n             arrhythmia, or psychiatric illness/social situations that would limit compliance with\n             study requirements.\n\n          -  Pregnant and/or breastfeeding. Patient must have a negative serum pregnancy test\n             within 7 days of study entry if premenopausal.\n\n          -  Known HIV-positivity.\n\n          -  Sentinel lymph node biopsy"
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "41", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 24, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02124902", 
            "org_study_id": "201404107"
        }, 
        "intervention": [
            {
                "arm_group_label": "Neoadjuvant docetaxel and carboplatin", 
                "intervention_name": "Docetaxel", 
                "intervention_type": "Drug", 
                "other_name": "Docefrez\u00ae, Taxotere\u00ae"
            }, 
            {
                "arm_group_label": "Neoadjuvant docetaxel and carboplatin", 
                "intervention_name": "Carboplatin", 
                "intervention_type": "Drug", 
                "other_name": "Paraplatin, Paraplatin-AQ"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Docetaxel", 
                "Carboplatin"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "May 15, 2014", 
        "link": {
            "description": "Alvin J. Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine", 
            "url": "http://www.siteman.wustl.edu"
        }, 
        "location": {
            "contact": {
                "email": "fademuyi@dom.wustl.edu", 
                "last_name": "Foluso Ademuyiwa, M.D., MPH", 
                "phone": "314-362-7201"
            }, 
            "facility": {
                "address": {
                    "city": "St. Louis", 
                    "country": "United States", 
                    "state": "Missouri", 
                    "zip": "63110"
                }, 
                "name": "Washington University School of Medicine"
            }, 
            "investigator": [
                {
                    "last_name": "Matthew Ellis, M.B., BChir., PH.D.", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Cynthia Ma, M.D., Ph.D.", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Adel Tabchy, M.D.", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Ron Bose, M.D., Ph.D.", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Michael Naughton, M.D.", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Steven Sorscher, M.D.", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Rama Suresh, M.D.", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Souzan Sanati, M.D.", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Julie Margenthaler, M.D.", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Rebecca Aft, M.D., Ph.D.", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Amy Cyr, M.D.", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Timothy Eberlein, M.D.", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "William Gillanders, M.D.", 
                    "role": "Sub-Investigator"
                }
            ], 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Co-clinical Trial in Triple Negative Breast Cancer Patients With Genoproteomic Discovery", 
        "overall_contact": {
            "email": "fademuyi@dom.wustl.edu", 
            "last_name": "Foluso Ademuyiwa, M.D., MPH", 
            "phone": "314-362-7201"
        }, 
        "overall_official": {
            "affiliation": "Washington University School of Medicine", 
            "last_name": "Foluso Ademuyiwa, M.D., MPH", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "April 2017", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "pCR rate will be calculated with 95% CI and will be tested against the reference pCR rate of 35% with standard chemotherapy", 
            "measure": "Pathological Complete Response (pCR) rate", 
            "safety_issue": "No", 
            "time_frame": "5 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02124902"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Washington University School of Medicine", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Washington University School of Medicine", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "June 2014", 
        "study_design": "Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}